MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
$819,918
Free Cash flow
-$5,687,568
Unit: Dollar
Positive Cash Flow Breakdown
Amortization of prepaid stock ba...
Issuance of common stock for ser...
Proceeds from the sale of common...
Others
Negative Cash Flow Breakdown
Net loss
Repayment of notes
Accrued expenses and other payab...
Others
Subscribe for Financial Insights
Page 1
Annual
123
Page 1
Cash Flow
2026-06-30
2025-06-30
Net loss
-18,862,710
-58,923,300
Issuance of common stock for services
4,993,748
51,348,000
Stock based settlement
75,000
-
Amortization of prepaid stock based expenses
8,498,492
4,621,230
Foreign currency transaction loss (gain)
32,152
-89,243
Refundable advance deposit
-
0
Depreciation expense
997
0
Deferred offering costs
-
0
Amortization of debt discounts
210,076
303,563
Derivative expense
-
333,596
Amortization of right-of-use assets
21,706
20,187
Change in fair value of derivative liabilities
13,709
212,450
Change in fair value of warrant liability
99,695
-
Loss (gain) on extinguishment of debt, net
133,071
-871,032
Allowance on refundable advance deposit
-
0
Non-cash interest expense
6,781
5,519
Accretion of put premium
-37,450
0
Gst receivable
8,117
2,405
Prepaid expenses
41,121
-1,379
Other current assets
33,471
-
Accounts payable
-183,012
187,732
Employee benefit liability
51,476
40,184
Accrued expenses and other payables
-401,049
677,889
Accrued interest
44,545
255,155
Operating lease liability
-14,189
-21,722
Net cash used in operating activities
-5,682,635
-405,168
Purchase of equipment
4,933
-
Proceeds from loans payable
-
0
Net cash used in investing activities
-4,933
-
Proceeds from convertible promissory notes, net of original issue discounts and issue costs
100,000
222,500
Proceeds from issuance of the initial preferred shares of series c preferred stock, net of issuance cost included as temporary equity
950,099
-
Proceeds from exercise of series c warrants
3,000,000
-
Repayment of convertible notes
203,350
8,000
Repayment of notes
671,777
122,788
Repayment of loans payable - related party
185,381
-
Proceeds from the sale of common stock, net of offering costs
3,314,458
0
Proceeds from note payable
75,000
320,000
Proceeds from loans payable - related parties
78,249
343,700
Deferred offering costs
-
264,656
Net cash provided by financing activities
6,457,298
490,756
Effect of exchange rate changes on cash
50,188
-94,585
Net increase (decrease) in cash
819,918
-8,997
Cash at beginning of year
12,088
21,085
Cash at end of year
832,006
12,088
Page 1
Unit: Dollar.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
PPCB Cash Flow Sankey Diagram
Sankey diagram visualizing PPCB cash flow for the period
Proceeds from the sale of
common stock, net of...
$3,314,458
Proceeds from exercise of
series c warrants
$3,000,000
Proceeds from issuance of
the initial...
$950,099
Proceeds from
convertible promissory...
$100,000
(-55.06%↓ Y/Y)
Proceeds from loans
payable - related...
$78,249
(-77.23%↓ Y/Y)
Proceeds from note
payable
$75,000
(-76.56%↓ Y/Y)
Net cash provided by
financing activities
$6,457,298
(1215.79%↑ Y/Y)
Effect of exchange rate
changes on cash
$50,188
(153.06%↑ Y/Y)
Canceled cashflow
$1,060,508
Net increase
(decrease) in cash
$819,918
(9213.24%↑ Y/Y)
Canceled cashflow
$5,687,568
Repayment of notes
$671,777
(447.10%↑ Y/Y)
Repayment of convertible
notes
$203,350
(2441.88%↑ Y/Y)
Repayment of loans payable
- related party
$185,381
Amortization of prepaid stock
based expenses
$8,498,492
(83.90%↑ Y/Y)
Issuance of common stock
for services
$4,993,748
(-90.27%↓ Y/Y)
Amortization of debt
discounts
$210,076
(-30.80%↓ Y/Y)
Change in fair value of
warrant liability
$99,695
Stock based
settlement
$75,000
Employee benefit
liability
$51,476
(28.10%↑ Y/Y)
Accrued interest
$44,545
(-82.54%↓ Y/Y)
Accretion of put premium
-$37,450
Amortization of right-of-use
assets
$21,706
(7.52%↑ Y/Y)
Non-cash interest
expense
$6,781
(22.87%↑ Y/Y)
Depreciation expense
$997
Net cash used in
operating activities
-$5,682,635
(-1302.54%↓ Y/Y)
Net cash used in
investing activities
-$4,933
Canceled cashflow
$14,039,966
Net loss
-$18,862,710
(67.99%↑ Y/Y)
Purchase of equipment
$4,933
Accrued expenses and
other payables
-$401,049
(-159.16%↓ Y/Y)
Accounts payable
-$183,012
(-197.49%↓ Y/Y)
Loss (gain) on
extinguishment of debt, net
$133,071
(115.28%↑ Y/Y)
Prepaid expenses
$41,121
(3081.94%↑ Y/Y)
Other current assets
$33,471
Foreign currency
transaction loss (gain)
$32,152
(136.03%↑ Y/Y)
Operating lease liability
-$14,189
(34.68%↑ Y/Y)
Change in fair value of
derivative liabilities
$13,709
(-93.55%↓ Y/Y)
Gst receivable
$8,117
(237.51%↑ Y/Y)
Buy us a coffee
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. (PPCB)